Baxter International Inc. has completed the acquisition of Gambro AB for $3.9 billion. Gambro, a privately-held Swedish company that focuses on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease and has annual sales of about $1.6 billion. The acquisition is expected to significantly increase the dialysis business for Baxter, whose kidney treatments currently focus on peritoneal dialysis.
Brik Eyre has been named president of the combined renal business. Prior to this role, Eyre served as general manager for Baxter’s BioPharma Solutions business.
Baxter reported in July that net income fell 11% in the second quarter on higher-than-expected costs connected to its purchase of Gambro.
"The combination of these two respected renal leaders—Baxter and Gambro—will enable Baxter to better serve health care providers and patients through a collective offering of innovative renal products and therapies,'' said Robert L. Parkinson, Jr., chairman and chief executive officer of Baxter. ''Together, we will advance the state of dialysis care for patients with kidney disease worldwide.''